论文部分内容阅读
目的观察缬沙坦对高血压病患者血清过氧化物酶体增生物激活受体-γ(PPAR-γ)、血红素氧合酶-1(HO-1)水平的影响及其肾脏保护作用关系。方法将35～65岁高血压病患者60例随机分为缬沙坦组(80～160 mg/d)30例和常规治疗组30例,接受16周的治疗。治疗期间监测血压,分别于治疗前和治疗16周后采用Elisa方法检测血清PPAR-γ、HO-1水平;并检测尿β2-微球蛋白和尿微量蛋白含量。结果缬沙坦治疗可显著降低高血压病患者血压水平(P<0.01),升高血清HO-1和PPAR-γ水平(P<0.01),降低尿β2-微球蛋白和尿微量蛋白含量(P<0.01)。结论缬沙坦在血压治疗达标的同时可显著降低尿蛋白,作用机制推测可能与其炎症调控作用有关。
Objective To observe the effect of valsartan on the serum levels of peroxisome proliferator-activated receptor-γ (PPAR-γ), heme oxygenase-1 (HO-1) and their renal protective effects in patients with essential hypertension . Methods Sixty patients aged 35 ~ 65 years old with hypertension were randomly divided into 30 cases of valsartan (80 ~ 160 mg / d) and 30 cases of routine treatment group, and received 16 weeks’ treatment. Blood pressure was monitored during treatment. Serum levels of PPAR-γ and HO-1 were measured by Elisa method before treatment and after 16 weeks of treatment respectively. Urinary β2-microglobulin and urinary microalbuminuria were measured. Results Valsartan could significantly decrease the blood pressure (P <0.01), increase the levels of serum HO-1 and PPAR-γ (P <0.01) and decrease the content of urinary β2-microglobulin and urinary microalbuminuria P <0.01). Conclusion Valsartan can significantly decrease urinary protein while blood pressure is up to standard. The mechanism of action may be related to the regulation of inflammation.